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AbsTrACT
Objective liver injury impacts hepatic inflammation 
in part via toll-like receptor (tlr) signalling. triggering 
receptor expressed on myeloid cells 2 (treM-2) 
modulates tlr4-mediated inflammation in bone marrow 
(BM)-derived macrophages but its function in liver 
injury is unknown. Here we hypothesised that the anti-
inflammatory effects of treM-2 on tlr signalling may 
limit hepatic injury.
Design treM-2 expression was analysed in livers of 
humans with various forms of liver injury compared with 
control individuals. acute and chronic liver injury models 
were performed in wild type and Trem-2-/- mice. Primary 
liver cells from both genotypes of mice were isolated for 
in vitro experiments.
results treM-2 was expressed on non-parenchymal 
hepatic cells and induced during liver injury in mice and 
man. Mice lacking treM-2 exhibited heightened liver 
damage and inflammation during acute and repetitive 
carbon tetrachloride and acetaminophen (aPaP) 
intoxication, the latter of which treM-2 deficiency was 
remarkably associated with worsened survival. liver 
damage in Trem-2-/- mice following chronic injury and 
aPaP challenge was associated with elevated hepatic 
lipid peroxidation and macrophage content. BM 
transplantation experiments and cellular reactive oxygen 
species assays revealed effects of treM-2 in the context 
of chronic injury depended on both immune and resident 
treM-2 expression. consistent with effects of treM-
2 on inflammation-associated injury, primary hepatic 
macrophages and hepatic stellate cells lacking treM-2 
exhibited augmented tlr4-driven proinflammatory 
responses.
Conclusion Our data indicate that by acting as a 
natural brake on inflammation during hepatocellular 
injury, treM-2 is a critical regulator of diverse types of 
hepatotoxic injury.
InTrODuCTIOn
Toll-like receptors (TLRs) are pattern recogni-
tion receptors that recognise conserved microbial 
molecules. A variety of TLRs are expressed on 
different liver cell types, including hepatocytes, 
hepatic stellate cells (HSCs) and resident Kupffer 
cells (KCs), with the latter cell type being located in 
significance of this study
What is already known on this subject?
 ► Increasing evidence suggests the gut-liver axis 
and innate immunity play a significant role in 
liver injury. Impaired intestinal permeability 
may promote liver inflammation due to the 
translocation of bacterial components into 
the liver.
 ► The consequent hepatic inflammatory response 
is in part mediated by toll-like receptors (TLRs). 
Fine tuning of TLR-driven inflammation during 
liver injury is key. The liver requires mechanisms 
to control the intensity and duration of 
TLR-driven cytokine production, which can 
contribute to the pathogenesis of acute and 
chronic liver disease.
 ► Triggering receptor expressed on myeloid cells  
2 (TREM-2) has been proposed to attenuate  
TLR4-mediated inflammation and to be  
important in injury responses in colon and  
brain.
What are the new findings?
 ► TREM-2 is expressed on non-parenchymal liver 
cells and is upregulated during diverse forms of 
liver injury in humans and mice.
 ► Trem-2-/- mice display increased liver 
damage and inflammation during acute and 
chronic carbon tetrachloride treatment and 
acetaminophen (APAP) intoxication. Effects of 
TREM-2 in the context of chronic liver injury 
are dependent on both liver resident and 
infiltrating immune cells.
 ► TREM-2 promotes survival during drug-induced 
APAP challenge.
 ► Liver injury in Trem-2-/- mice is associated with 
elevated levels of reactive oxygen species 
and lipid peroxidation.
 ► In line with TREM-2 effects on inflammation 
and injury, Kupffer cells and hepatic stellate 
cells isolated from Trem-2-/- mice exhibit 
increased proinflammatory cytokine and 
chemokine production upon TLR4  
stimulation.
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the hepatic sinusoids and the first cells to encounter gut derived 
danger signals, such as lipopolysaccharide (LPS).1–3 The crucial 
role of TLR signalling within the liver is highlighted by studies 
showing that Tlr4-/- mice are protected from various forms of 
liver injury.4 5 Illustrating the critical role of the fine tuning of 
TLR4-driven inflammation during liver injury, interleukin 1 
receptor-associated kinase-M (IRAK-M) and A20, prototypical 
negative regulators of TLR4 signalling, protect from alcohol-in-
duced and ischaemia/reperfusion liver injury, respectively.6 7 
The triggering receptor expressed on myeloid cells 2 
(TREM-2) is a relatively recent described regulator of TLR-me-
diated inflammatory responses. Similar to IRAK-M and A20, 
TREM-2 acts to dampen TLR-driven cytokine responses 
within bone marrow derived macrophages (BMDM).8 This is 
in contrast to TREM-1 which augments TLR-induced inflam-
mation.9 TREM-1 and TREM-2 both signal via the ITAM 
motif of the adaptor protein DNAX-activation protein 12, 
which becomes tyrosine phosphorylated leading to increases 
in intracellular calcium and extracellular regulated kinase 
(ERK1/2) phosphorylation.9–11 TREM-1 is expressed on 
KCs and HSCs and is important in promoting inflamma-
tion-driven hepatocellular carcinoma and diethylnitrosamine 
liver injury.12 TREM-2 has been shown to be expressed on 
KCs where it serves to control liver stage malarial infec-
tion.13 14 Given that TREM-2 has been proposed to atten-
uate TLR4-mediated inflammation and has previously been 
shown to be important in injury responses in the colon and 
brain, we undertook this study to examine if it could play a 
role in liver injury and inflammation.11 15–17
MATerIAls AnD MeTHODs
Patients
To perform gene expression analysis at mRNA level, liver tissue 
was obtained from control individuals (n=21) and patients with 
liver cirrhosis of different aetiology (n=23). Patient character-
istics and liver injury-related serology are indicated in online 
supplementary table 1. Tissue samples of normal liver used as 
controls were obtained from background non-neoplastic tissue of 
liver resection specimens for colorectal metastasis. The selected 
sections were located furthest away from the tumour mass lesion. 
Samples and data from patients included in this study were 
provided by the Basque Biobank (http://www. biobancovasco. 
org) and were processed following standard operation proce-
dures with appropriate approval by the Clinical Research Ethics 
Committees of the Basque Country and Donostia Hospital. An 
informed consent was obtained from all subjects. Human hepatic 
myofibroblasts were isolated from livers of adult male patients 
after surgical resection as approved by the Newcastle and North 
Tyneside Local Research Ethics Committee, subject to patient 
consent (10/H0906/41).
experimental models of liver injury
Wild type (WT) and Trem-2 knockout (Trem-2-/-) male mice 
(25–30 g) were intraperitoneally injected one time (acute) or 
two times a week for 8 weeks (chronic) with carbon tetrachlo-
ride (CCl4) at 2 µl/g body weight (CCl4: olive oil at 1:1 (vol:vol) 
(acute) and 1:3 (vol:vol) (chronic)). For the acetaminophen 
(APAP) model WT and Trem-2-/- male mice (25–30 g) were over-
night-starved and intraperitoneally injected once with APAP 
(Sigma-Aldrich) at a concentration of 300 mg/kg or 500 mg/kg 
dissolved in sterile warm saline. For survival studies, mice were 
injected with a lethal dose of APAP (750 mg/kg) and survival was 
monitored every hour for 30 hours, after which it was moni-
tored every day. Animal care and procedures were approved 
by the Animal Care and Use Committee of the Medical Univer-
sity of Vienna and the Austrian Ministry of Sciences as well 
as by the Animal Experimentation Ethics Committee (CEEA) 
of Biodonostia Research Institute and the Newcastle Ethical 
Review Committee under a UK Home Office project license. 
Trem-2-/- mice backcrossed onto a >98% C57BL/6 background 
were obtained from Marco Colonna (Washington University) 
and generated as previously described.8 For all in vivo experi-
ments, we used age-matched (8–10 week old) male Trem-2-/- mice 
and WT controls bred at the Medical University of Vienna or 
Biodonostia Research Institute. For bone marrow (BM) trans-
plantation, Trem-2-/- mice were crossed with mice that ubiqui-
tously express green-fluorescent protein (GFP) on a C57BL/6 
background (WT-UbGFP+) to generate (Trem-2-/-/Ub-GFP+) 
mice.
Isolation of mouse hepatocytes, KCs, HsCs, bMDMs and 
treatments
Hepatocytes, KCs and HSCs were isolated from mice and rats as 
previously described.18 19
Additional Materials and Methods are included as online 
supplementary files.
resulTs
TreM-2 is upregulated during liver injury in mice and humans
We first examined TREM-2 transcript levels in a cohort of control 
(n=21) and diseased liver (n=23) as described in online supple-
mentary table 1. By grouping all the cirrhotic livers despite of 
different disease aetiology (HCV or HBV infection, HCV/HIV 
coinfection and alcoholic or other aetiology) and comparing 
these with control liver tissues, we could observe significantly 
elevated TREM-2 transcript levels in cirrhotic versus control 
liver (figure 1A). Correlating these data with levels of markers 
of hepatocyte injury, fibrosis and inflammation revealed that 
increases in TREM-2 expression correlated with collagen levels 
and with alanine aminotransferase, aspartate aminotransferase 
and the inflammation markers IL-8 and IL-6 (figure 1B,C, online 
supplementary figure 1), suggesting that increases in TREM-2 
may serve to dampen hepatic inflammation and injury. Evalu-
ating TREM-2 expression using immunohistochemistry in an 
independent cohort of human control liver and cirrhotic liver of 
variable aetiology (online supplementary table 2), verified that 
TREM-2 expression was more extensive in diseased compared 
with control liver (online supplementary figure 2). Mild cyto-
plasmic TREM-2 immunostaining was observed in monocytes 
and KCs in control liver, while there were no TREM-2 positive 
endothelial cells or lymphocytes. TREM-2 immunohistochemical 
expression in cirrhotic liver was observed in neutrophils, mono-
cytes and macrophages in the fibrous septa, within sinusoids and 
in parenchymal inflammatory foci. Collagen deposition in fibrous 
septa was confirmed in cirrhotic versus control liver by Sirius 
red staining (online supplementary figure 2). Further, Trem-2 
was upregulated during both acute and repetitive CCl4 induced 
significance of this study
How might it impact on clinical practice in the foreseeable 
future?
 ► Strategies that aim to therapeutically activate this receptor 
may provide a novel route towards suppressing inflammation 
caused by toxin-induced hepatocellular injuries.
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injury in mice compared with olive oil controls and augmented 
Trem-2 levels occurred during bile duct ligation compared with 
sham operated mice (figure 1D–F). In the chronic CCl4 model, 
we noted that on cessation of liver damage levels of Trem-2 tran-
script declined over a 10-day period of recovery, but remained 
slightly higher than in controls (figure 1E). We conclude liver 
injury in mice and man is associated with a substantial induction 
in the expression of TREM-2 indicating a role for the receptor 
in hepatic wound repair.
TreM-2 is expressed on non-parenchymal liver cells and is 
upregulated during HsC activation
Flow cytometry and qRT-PCR for TREM-2 in murine hepatic 
cells demonstrated expression on KCs and quiescent HSCs, but 
not on hepatocytes demonstrating that TREM-2 was expressed 
by non-parenchymal liver cells (figure 2A,B). We next investi-
gated the expression of Trem-2 during HSC transdifferentia-
tion, which was induced in vitro by culturing freshly isolated 
murine quiescent HSCs on plastic for 7 days. By doing so, we 
could observe that Trem-2 mRNA expression was strongly 
induced during mouse HSC transdifferentiation in vitro. This 
response was conserved as TREM-2 expression during activa-
tion in vitro was similarly increased in rat and human HSCs 
(figure 2C). Examining the activation status of both genotypes 
of HSCs revealed that activated Trem-2-/- HSCs displayed similar 
α-smooth muscle actin (encoded by Acta2) and α1(I) procol-
lagen (encoded by Col1a1) expression to WT (figure 2D). To 
address if Trem-2 was induced during HSC activation in vivo, we 
isolated HSCs from bile duct ligated or chronic CCl4 injured rats. 
Trem-2 was significantly induced in HSCs in vivo during liver 
injury (figure 2E). Together, these data suggested that conserved 
increases in TREM-2 expression during HSC activation might 
play a role during chronic liver injury, a process where HSCs 
are crucial fibrogenic effector cells and are important mediators 
of innate immunity that cross-talk with other liver resident and 
infiltrating cells during hepatocellular damage.20 21
TreM-2 attenuates chronic hepatic inflammation and injury
To formally investigate a function for TREM-2 in chronic liver 
disease, we employed a genetic approach comparing damage-in-
duced responses of Trem2-/- mice with WT controls. We thus 
performed chronic CCl4 injury and first determined differences 
in hepatic levels of the inflammatory mediator monocyte chemo-
attractant protein 1 (Mcp1). We observed significantly elevated 
Mcp1 mRNA in WT at peak injury (day 1 after the final admin-
istration of CCl4) which declined close to control levels with 
recovery (day 5 postinjury) (figure 3A). Similarly, as expected, 
levels of the matrix metalloproteinase-13 (Mmp13) transcript 
were induced with peak injury in WT liver and declined to 
control levels with recovery (figure 3A). Both Mcp1 and Mmp13 
were induced at significantly elevated levels in peak injured Trem-
2-/- livers compared with WT, although with recovery no differ-
ences were observed between genotypes. Intriguingly we did 
not observe differences for damage-induced expression of inter-
leukin-6 (Il6), interleukin-1 beta (Il1b), tumour necrosis factor-
alpha (Tnf) or transforming growth factor beta-1 (Tgfb1) (online 
supplementary figure 3). Although at peak injury there was a 
tendency for higher Acta2 and Col1a1 liver transcript levels in 
Trem-2-/- mice, Sirius red staining verified that TREM-2 exerted 
only minor effects on fibrosis (online supplementary figure 4). 
Figure 1 Expression of TREM-2 during human and mouse liver disease. (A) qRT-PCR analysis of TREM-2 expression in normal human liver (controls) 
and cirrhotic samples. (B,C) Correlation between TREM-2 and COL1A1 levels (B) or ALT (C). n=21 controls and 23 cirrhotic livers. (D) qRT-PCR of Trem-
2 expression in livers of mice after the indicated acute CCl4 time points. Olive oil treated mice were used as controls. n=3 mice per condition and time 
point. (E,F) Trem-2 mRNA expression in the liver of mice treated with CCl4 for 12 weeks and sacrificed 1, 3, 7 or 10 days after the last CCl4 injection (E) 
and 14 or 21 days after BDL (F). n=3–5 (E) and 4–5 mice per time point (F). Statistical analysis used was Mann Whitney test (A) and non-parametric 
Spearman’s correlation test (B,C). Data represent mean±SEM and **,*** denote a P value of ˂0.01 and ˂0.001, respectively versus olive oil (D,E) 
or sham (F) determined using one-way analysis of variance, followed by Tukey’s posthoc test. ALT, alanine aminotransferase; BDL, bile duct ligation; 
CCl4, carbon tetrachloride; TREM, triggering receptor expressed on myeloid cells. 
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Augmented inflammation during peak injury in Trem-2-/- livers 
was however associated with significantly enhanced transam-
inase release, suggesting that increased death and damage of 
hepatocytes occurs in the absence of TREM-2 (figure 3B). In 
agreement, histology disclosed significantly more necrosis and 
apoptosis in Trem-2-/- livers but unremarkable effects of TREM-2 
on fibrosis (figure 3C,D). Monitoring transcription of genes 
associated with cellular stress (Heme oxygenase 1 (Hmox-1), 
cytochrome b-245 heavy chain (Cybb), nitric oxide synthase 2 
(Nos2), Heat-shock family member 70 (Hspa1b)) and apoptosis 
(B-cell CLL Lymphoma 2 (Bcl-2), BCL2-like 1 (Bcl2l1), BCL-2 
associated-X protein (Bax)) revealed that these pathways were 
both operational at peak injury and that levels of the stress-as-
sociated marker Hspa1b and the antiapoptotic gene Bcl2l1 were 
significantly upregulated in Trem-2-/- compared with WT livers 
(figure 3E). We conclude that an important function of TREM-2 
is to protect against excessive liver injury in the context of itera-
tive hepatotoxic damage.
Combined action of liver resident and infiltrating cells are 
required for TreM-2 to dampen chronic injury
To understand the contribution of TREM-2 expression on inflam-
matory cells versus HSCs to liver damage, we next reconstituted 
lethally irradiated WT or Trem-2-/- mice with WT or Trem-2-/- 
BM that ubiquitously expresses GFP within both genotypes, to 
generate four groups of mice. Nearly 100% of blood leucocytes 
were GFP+ within all groups, proving successful transplantation 
(online supplementary figure 5). Corroborating observations 
that TREM-2 attenuated chronic liver injury (figure 3B), elevated 
transaminases were observed in Trem-2-/- mice reconstituted with 
Trem-2-/- BM compared with WT (figure 4A). Although Trem-
2-/- mice reconstituted with WT BM displayed a tendency for 
more liver damage compared with WT mice transplanted with 
WT BM, significantly elevated damage was only observed when 
TREM-2 was deficient within immune and resident cells (such 
as HSCs), demonstrating TREM-2 protects from immune-medi-
ated hepatocellular damage via its combined functions in these 
cell types. These observations were confirmed by histology 
(figure 4B). Monitoring hepatic immune cell influx revealed 
equal numbers of recruited neutrophils between the groups of 
mice during chronic injury, while recruited monocyte derived 
macrophages were significantly elevated in Trem-2-/- mice recon-
stituted with Trem-2-/- BM, which correlated with elevated levels 
of Mcp1 (figure 4C,D, online supplementary figures 5 and 6). 
Together, these observations further support the concept that 
in the context of chronic CCl4 injury, TREM-2 dampens liver 
injury and indicates that these effects are dependent on both resi-
dent and infiltrating immune cells.
KC and HsC expressed TreM-2 dampens Tlr4-mediated 
inflammation
We next focused on the effects of deletion of TREM-2 on the 
inflammatory properties of resident KCs and HSCs (figure 2) 
following TLR activation. While there was no effect of 
Figure 2 TREM-2 expression in non-parenchymal liver cells and activated HSCs during liver injury. (A) TREM-2 expression in primary mouse 
hepatocytes, KCs or qHSCs detected by flow cytometry. Red and blue lines depict the isotype and TREM-2 antibodies respectively. (B) qRT-PCR analysis 
of Trem-2 expression in various liver cell types. n=10 (hepatocytes), 4 (KCs) and 5 (qHSCs). (C) TREM-2 expression in mouse, rat and human HSCs 
during trans-differentiation in vitro at day 1 (quiescent) and day 7 (activated) after the isolation. n=3. (D) Transcript levels of Acta2 and Col1a1 in WT 
and Trem-2-/- activated mouse HSCs. n=3. (E) Trem-2 expression in rat HSCs activated in vivo from CCl4 and BDL treated rats. n=4–5 per condition. 
Data represent mean±SEM and *, **, *** denote a P value of ˂0.05, ˂0.01 and ˂0.001, respectively versus quiescent (C) or olive oil or sham (E) 
and statistical analysis used was unpaired Student’s t-test. Data in (C,E) are representative of two and in (D) is representative of three independent 
experiments BDL, bile duct ligation; CCl4, carbon tetrachloride; HSCs, hepatic stellate cells; KCs, Kupffer cells; qHSC, quiescent HSC; TREM, triggering 
receptor expressed on myeloid cells; WT, wild type. 
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TREM-2 deficiency within KCs on LPS-driven Mcp1 tran-
scription (online supplementary figure 7), LPS stimulated 
TREM-2 deficient KCs displayed increased induction of Il6, 
Tnf, Il1b and C-X-C motif chemokine ligand 1 (Cxcl1), as 
early as 1 hour post-treatment (figure 5A). As dysbiosis of gut 
bacteria is important in CCl4-induced liver injury and inflam-
mation,22 23 we next set to more closely mimic this scenario 
by treating KCs with the intestinal bacterium Escherichia coli 
(E. coli). E. coli treatment also resulted in increased proin-
flammatory cytokine transcription in Trem-2-/- KCs compared 
with WT (figure 5B). ELISA data verified that lack of TREM-2 
enhanced the induction of inflammatory mediators following 
challenge with either LPS or E. coli (online supplementary 
figure 8). As we had observed increased Mcp1 production in 
vivo following chronic injury (figures 3 and 4), but no effect 
of Trem-2 expression within KCs on LPS-driven induced 
Figure 3 TREM-2 impacts chronic CCl4-induced liver injury. (A–E) WT and Trem-2
-/- mice were treated with CCl4 for 8 weeks, sacrificed 1 or 5 
days after the last CCl4 injection and (A) liver Mcp1, Mmp13 (B) ALT and AST levels were determined. (C) Necrosis, apoptosis and fibrosis histology 
score from WT and Trem-2-/- mice that were treated with CCl4 for 8 weeks and sacrificed 1 day after the last CCl4 injection. (D) Representative H&E 
(Magnification is 10x) from day 1 are depicted. (E) Transcript levels of the indicated genes associated with stress and apoptosis were determined. 
n=3 mice per genotype (olive oil) and 4–8 mice per genotype (CCl4 both time points). Data represent mean±SEM and *, ** denote a P value of ˂0.05 
and ˂0.01, respectively versus WT at the same time point (Mann Whitney test). ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCl4, 
carbon tetrachloride; TREM, triggering receptor expressed on myeloid cells; WT, wild type. 
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MCP-1 production (online supplementary figure 7), we spec-
ulated that HSCs might be a source for MCP-1 production in 
vivo. Indeed, examining TLR4-driven inflammation in both 
genotypes of activated HSCs revealed that LPS and E. coli 
treatment resulted in augmented Cxcl1 and MCP-1 levels in 
activated Trem-2-/- HSC versus WT (figure 5C,D). Augmented 
inflammation in Trem-2-/- opposed to WT HSC was specific 
for TLR4-dependent signalling as LPS but not interleukin 
(IL)-1β treatment resulted in enhanced inflammation (online 
supplementary figure 9A). While IL-1β and TNF-α treatment 
of KCs was in general less proinflammatory compared with 
LPS, TREM-2 deficiency only led to augmented inflamma-
tion in response to LPS, further suggesting that this receptor 
does not impinge directly on TNF-α and IL-1β signalling 
cascades in non-parenchymal cells and ratifying specificity for 
TLR4-mediated signalling (online supplementary figure 9B). 
Figure 4 TREM-2 expression within liver resident and infiltrating immune cells is required for dampening of chronic CCl4 induced liver injury. (A–D) 
WT mice reconstituted with WT-GFP+bone marrow (WT-WT), Trem-2-/- mice reconstituted with Trem-2-/--GFP+bone marrow (Trem-2-/--Trem-2-/-) or 
chimeric mice (WT-Trem-2-/-) and (Trem-2-/--WT) were treated with CCl4 for 8 weeks and sacrificed 1 day after the last CCl4 injection and (A) serum ALT 
and AST levels, (B) H&E stain of livers (C) total number of macrophages (defined as CD45+CD11b+Ly6C+Ly6G-F4/80+GFP+ cells, (online supplementary 
figure 5) normalised to liver weight and (D) liver Mcp1 transcript levels were determined. Data represent mean±SEM and *, **, ***, **** denote a 
P value of ˂0.05, ˂0.01, ˂0.001 and <0.0001 respectively versus the indicated genotype (one-way analysis of variance, followed by Tukey’s posthoc). 
n=3 per genotype (olive oil) and 3–5 per genotype (CCl4). ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCl4, carbon tetrachloride; 
GFP, green fluorescent protein; TREM, triggering receptor expressed on myeloid cells; WT, wild type. 
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To corroborate that TREM-2 could dampen TLR4 responses 
within HSCs, we next performed gain of function exper-
iments. TREM-2 overexpression dampened LPS-induced 
MCP-1 and IL-6 levels within human LX2 HSCs (figure 5E). 
We conclude that TREM-2 attenuates TLR4-mediated inflam-
matory responses of both KC and HSC.
TREM-2 has been reported to modulate MAPK signalling 
and phosphorylation including ERK, p38 and Jun N-terminal 
kinase (JNK) phosphorylation, which are early and critical 
signal transduction events in TLR4-induced cytokine produc-
tion.11 24 25 We next examined effects of TREM-2 on TLR4-me-
diated MAPK activation. E. coli-induced phosphorylation of 
ERK and p38 was potentiated in Trem-2-/- KCs, while there 
was a minor decrease in JNK activation, compared with WT 
KCs (figure 5G). Whereas decreases in JNK activation were 
more pronounced in response to LPS in Trem-2-/- compared 
with WT KCs, LPS-induced ERK phosphorylation was 
similarly augmented in Trem2-/- KC, suggesting TREM-2 func-
tions to dampen the activation of ERK downstream of TLR4 
(figure 5F,G). However, we observed no effect of TREM-2 
deletion on TLR4-mediated nuclear factor kappa B (NF-κB) 
activation (figure 5F,G). We conclude that within resident liver 
macrophages, TREM-2 dampening of TLR4-driven inflamma-
tion is associated with an early attenuation of MAPK phos-
phorylation, particularly ERK activation.
TreM-2 blunts acute CCl4 and APAP-induced liver 
inflammation and injury
Given the influence of TREM-2 on acute inflammatory 
responses of hepatic non-parenchymal cells, we determined 
if the receptor is functionally involved in controlling the 
response to acute toxic liver injury. We therefore performed 
two distinct acute liver injury models, administering mice 
Figure 5 Cytokine responses and mitogen activated protein kinase (MAPK) signalling in WT and Trem-2-/- non-parenchymal hepatic cells after TLR4 
stimulation. (A,B) WT and Trem-2-/- KCs were treated with LPS (100 ng/mL) (A) or (B) heat-killed E. coli (2×107 CFU/mL) for the indicated time points 
(n=4–5 per condition and time point) and levels of Cxcl1, Tnf, Il6 and Il1b were determined by qRT-PCR. (C, D) Cxcl1 (C) and MCP-1 (D) levels in WT 
and Trem-2-/- activated mouse HSCs treated with 2×107 CFU/mL heat-killed E. coli or 100 ng/mL LPS. n=3 (E. coli) and 4 (LPS). (E) Human HSC LX-2 
cells were transfected with a control or TREM-2 overexpressing plasmid (n=4 per condition) and 36 hours post-transfection stimulated with 100 ng/
mL LPS for 3 hours and levels of TREM-2, MCP-1 and IL-6 determined by qRT-PCR. (F,G) WT and Trem-2-/- KCs were treated with 100 ng/mL LPS (F) 
or 2×107 CFU/mL heat-killed E. coli (G) for the indicated time points and phosphorylation of ERK1/2, p38, JNK, p65 and IκB-α degradation was 
determined by western blotting. Data represent mean±SEM and *, **, ***, **** denote a P value of ˂0.05, ˂0.01, ˂0.001 and <0.0001, respectively 
versus WT at the same time point (one-way analysis of variance, followed by Tukey’s posthoc test). Data in (C,D) are representative of two 
independent experiments. Cxcl1, C-X-C motif chemokine ligand 1; ERK, extracellular regulated kinase; HSCs, hepatic stellate cells; JNK, Jun N-terminal 
kinase; KCs, Kupffer cells; LPS, lipopolysaccharide; MCP-1, monocyte chemoattractant protein-1; TREM, triggering receptor expressed on myeloid cells; 
WT, wild type. 
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with either a single dose of CCl4 or APAP overdose, the latter 
being a common cause of acute human liver failure associated 
with mitochondrial dysfunction, stress, lipid peroxidation 
and liver necrosis.26
Twelve hours postacute CCl4 injury, Trem-2
-/- mice 
displayed elevated liver transaminases compared with WT, 
this effect was associated with elevated levels of the neutro-
phil chemoattractant Cxcl1 and increased hepatic neutro-
phil recruitment 24 hours postinjury, as determined using 
immunohistochemistry (figure 6A–D). By contrast, there 
were unremarkable effects of TREM-2 deletion on macro-
phage recruitment (data not shown). To confirm these data, 
we next isolated inflammatory cells from the livers of both 
genotypes of mice 24 hours post CCl4 injury and using 
flow cytometry again observed a strong tendency (P=0.06) 
for elevated hepatic neutrophil numbers in Trem2-/- mice 
compared with WT controls (figure 6E).
Similar to acute CCl4 injury, following sublethal APAP 
intoxication, Trem-2-/- mice displayed augmented trans-
aminase levels, more extensive parenchymal necrosis 
Figure 6 TREM-2 blunts acute CCl4 induced hepatic inflammation and injury. (A–C) Serum AST/ALT (A), representative H&E stains of liver (B) and 
qRT-PCR of liver Cxcl1 (C) postacute CCl4 treatment of WT and Trem-2
-/- mice for the indicated times. (D) Representative images of liver sections 
immunostained for neutrophils (anti-neutrophil marker (NIMP)) of WT and Trem-2-/- mice 24 hours after acute CCl4 treatment. Arrows denote positively 
stained cells. Manual counts for NIMP-positive cells in livers post-CCl4 treatment are depicted. (E) Representative flow cytometry plot of hepatic 
neutrophils of WT and Trem-2-/- mice 24 hours postacute CCl4 treatment. Total number of neutrophils normalised to liver weight are indicated. All data 
represent mean±SEM and *, ** denote a P value of ˂0.05 and ˂0.01, respectively versus WT at the same time point. n=5 mice per condition (A–C), 
three mice per condition (D) and n=6–10 mice per condition and are pooled data from two independent experiments (E). Statistical analysis used was 
unpaired Student’s t-test. Scale bar in (B) indicates 200 µm. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCl4, carbon tetrachloride; 
Cxcl1, C-X-C motif chemokine ligand 1; TREM, triggering receptor expressed on myeloid cells; WT, wild type. 
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and increased neutrophil content compared with WT 
(figure 7A–C). However, in this model, Trem-2-/- mice also 
displayed elevated macrophage content, which was asso-
ciated with elevated levels of Mcp1 (figure 7B–D). These 
data suggested that enhanced pathogen-associated molec-
ular pattern (PAMP)-driven inflammation from non-paren-
chymal liver cells in Trem-2-/- mice might be a driver for the 
elevated liver damage. To exclude a toxic effect of APAP on 
parenchymal cells, we isolated both genotypes of hepato-
cytes, treated them with APAP and evaluated cell viability. 
While APAP dose dependently killed hepatocytes, cell death 
was not elevated in TREM-2 deficient hepatocytes, in fact, 
surprisingly there was a small although statistically signif-
icant tendency that viability was increased (figure 7E). To 
further examine the consequences of the enhanced liver 
damage in Trem-2-/- mice, we administered both geno-
types of mice with a lethal dose of APAP and monitored 
survival. Strikingly, while 70% of WT mice survived up until 
72 hours, all Trem-2-/- mice died within 25 hours (figure 7F). 
We conclude that TREM-2 is critical for appropriate damp-
ening of the acute liver damage response and its associated 
inflammatory reaction, with the immune receptor therefore 
being essential for preventing lethal APAP intoxication.
TreM-2 suppresses injury-induced hepatic rOs and lipid 
peroxidation
Previous observations from our laboratory indicate that 
TREM-2 can modulate peroxisome proliferator-activated 
receptor (PPAR) and nuclear receptor activities that regulate 
lipid-associated pathways.27 Inflammation, particularly that 
mediated by CCl4 and APAP intoxication is associated with 
enhanced lipid peroxidation, which can result in hepatocyte 
death.28–30 In search for a unified mechanism behind the 
elevated liver injury of Trem-2-/- mice following chronic CCl4 
and acute APAP intoxication, we next monitored levels of 
4-hydroxynonenal (4-HNE), a surrogate for lipid peroxida-
tion.30 Both, at peak injury following chronic CCl4 treatment 
and APAP intoxication, elevated 4-HNE levels were observed 
in the livers of Trem-2-/- mice (figure 8A,B). To confirm these 
data, in an independent experiment, we next isolated livers 
from both genotypes of mice 24 hours post APAP treatment 
Figure 7 TREM-2 dampens acetaminophen-induced liver injury. (A) WT and Trem-2-/- mice were injected with 300 mg/kg APAP and 24 hours 
postinjury ALT and AST levels were determined. (B) Representative H&E, F4/80 and Ly-6G stains from the groups of mice are depicted. Trem-2-/-
 mouse liver exhibit more extensive parenchymal necrosis compared with WT liver. Arrows denote positively stained cells. (C) Manual counts for 
F4/80 and Ly6G positive cells in livers post-APAP treatment. (D) WT and Trem-2-/- mice were injected with 500 mg/kg APAP, and liver Mcp1 levels were 
determined. (E) WT and Trem-2-/- hepatocytes were treated with indicated doses of APAP for 24 hours and cellular viability evaluated. (F) WT and 
Trem-2-/- mice were injected with 750 mg/kg APAP and survival was monitored. Data represent mean±SEM and *, **, ***, **** denote a P value of 
˂0.05, ˂0.01, ˂0.001 and <0.0001, respectively versus WT. n=5 mice per genotype (A–D), 6 hepatocytes per genotype (E) or 9 mice per genotype (F). 
Statistical analysis used was unpaired Student’s t-test (A–E) and Log-rank (Mantel-Cox) test (F). Scale bar in (B) indicates 50 µm (left panel) or 200 µm 
(right panel). Data in (E) are representative of two independent experiments. ALT, alanine aminotransferase; AST, aspartate aminotransferase; APAP, 
acetaminophen; TREM, triggering receptor expressed on myeloid cells; WT, wild type. 
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Figure 8 TREM-2 impacts hepatic lipid peroxidation and macrophage ROS levels. (A,B) Representative hepatic 4-HNE stain from WT and Trem-2-/-
 mice that were either treated with CCl4 for 8 weeks and sacrificed 1 day after the last CCl4 injection (A) or injected with 300 mg/kg APAP for 24 hours 
(B). n=3 mice per genotype (olive oil) or 4–8 mice per genotype (CCl4) or 5 mice per genotype (APAP). (C) 4-HNE content was determined by ELISA 
in livers of mice injected with 300 mg/kg APAP for 24 hours. n=5–7 per genotype. (D) Representative hepatic 4-HNE stain from WT mice reconstituted 
with WT-GFP+BM (WT-WT), Trem-2-/- mice reconstituted with Trem-2-/--GFP+BM (Trem-2-/--Trem-2-/-) or chimeric mice (WT-Trem-2-/-) and (Trem-2-/--WT) 
that were treated with CCl4 for 8 weeks and sacrificed 1 day after the last CCl4 injection. n=3 per genotype (olive oil) and 3–5 per genotype (CCl4). 
Scale bar 5× indicates 50 µm and 20× indicates 200 µm. (E,F) WT and Trem-2-/- KCs (E) or BMDM (F) were treated with 100 ng/mL LPS for 3 hour and 
total cellular ROS levels were determined using flow cytometry for dihydrorhodamine 123. n=3–4 per genotype and condition and a representative 
histogram is shown. (G) Oxygen consumption rate of naive and LPS-treated BMDM was evaluated. n=4–5 per condition. Data in (C,G) represent 
mean ±SEM and * and **** denote a P value of< 0.05 and  <0.0001 versus WT. Data in (E) are representative of 3 and (F,G) of two independent 
experiments. Scale bar in (A,B) indicates 50 µm. APAP, acetaminophen; BMDM, bone marrow derived macrophages; CCl4, carbon tetrachloride; GFP, 
green fluorescent protein; 4-HNE, 4-hydroxynonenal; KCs, Kupffer cells; LPS, lipopolysaccharide; ROS, reactive oxygen species; TREM, triggering 
receptor expressed on myeloid cells; WT, wild type. 
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and could indeed observe significantly elevated 4-HNE 
levels as determined using ELISA (figure 8C). Examining 
4-HNE staining revealed that lipid peroxidation appeared 
to be most intense around hepatic venules, where inflamma-
tory cells reside, suggesting that elevated lipid peroxidation 
might occur through enhanced reactive oxygen species (ROS) 
levels within resident or infiltrating immune cells. Supporting 
this idea, elevated lipid peroxidation following chronic CCl4 
treatment was only observed when TREM-2 was deficient 
within resident and infiltrating immune cells (figure 8D). As 
the ability of TREM-2 to dampen liver damage following 
chronic CCl4 treatment depended on TREM-2 expression 
in both resident and infiltrating cells (figure 4), these data 
further linked elevated lipid peroxidation to injury and addi-
tionally suggested that this effect could be associated with 
enhanced ROS levels within Trem-2-/- resident and liver infil-
trating immune cells. However, examining ROS levels within 
both genotypes of KCs revealed similar levels in both basal 
and LPS-driven ROS (figure 8E). Considering increased lipid 
peroxidation in Trem-2-/- mice was associated with elevated 
MCP-1 and newly recruited monocyte derived hepatic macro-
phage levels, we next asked if elevated liver damage in Trem-2-
/- mice could be associated with differential ROS levels within 
injury-associated inflammatory monocytes that repopulate 
the liver. We used BMDM to model this. Strikingly, Trem-2-
/- BMDM exhibited higher baseline and LPS-induced ROS 
levels (figure 8F). Mitochondria via the process of oxidative 
phosphorylation and the NADPH oxidase complex produce 
ROS, so we next set out to validate these findings as well as 
determine the cellular source for the elevated ROS in Trem-
2-/- macrophages. Intriguingly, when assessing mitochondrial 
activity, we observed that Trem-2-/- BMDM exhibited higher 
baseline oxidative phosphorylation and maximal respiration, 
suggesting that this metabolic signature might be responsible 
for the enhanced ROS (figure 8G). These data suggest that 
TREM-2 affects lipid peroxidation and subsequent damage of 
hepatocytes by skewing metabolic pathways and ROS genera-
tion within newly recruited liver macrophages following liver 
injury.
PAMPs are upstream of TreM-2 during liver injury
Thus far our observations indicated an importance for TREM-2 
in dampening hepatic injury and inflammation. In an effort 
to demonstrate that the upstream driver for acute liver injury 
in TREM-2 deficient mice was PAMPs and associated TLR4 
signalling downstream of gut bacteria, we administered both 
genotypes of mice antibiotics and evaluated liver injury and 
inflammation post-CCl4 treatment versus animals that did not 
receive antibiotics. Eight hours postacute CCl4 injection, we 
orally gavaged all groups of mice with 4 kDa FITC-Dextran, to 
evaluate intestinal permeability as previously described22 and 
sacrificed all animals 4 hours later, that is, we administered CCl4 
for a total of 12 hours. Although there was a trend that anti-
biotic treatment increased intestinal permeability, serum FITC 
levels were unaltered between genotypes in either the presence 
or absence of antibiotics post-CCl4 treatment (figure 9A). Trem-
2-/- mice exhibited exaggerated transaminase release compared 
with WT following acute CCl4 treatment, as previously observed 
(figure 7A) and notably antibiotics abolished this (figure 9B). 
Evaluating transcript levels of Il1b and Il6, revealed that anti-
biotic treatment also reverted the augmented hepatic inflamma-
tion of Trem-2-/- mice to WT levels (figure 9C). Together, these 
important data show that following acute liver injury, differences 
in altered intestinal permeability of TREM-2 deficient mice do 
not contribute to their exaggerated liver damage. They further 
support the concept that TREM-2 dampens PAMP-derived 
signals that emanate from gut bacteria which perpetuate hepatic 
injury and inflammation.
DIsCussIOn
Unresolved inflammation is a pathogenic component of liver 
disease and contributes to progressive liver damage and fibrosis. 
Altered intestinal permeability during liver injury results in 
leakage of PAMPs that are recognised by non-parenchymal liver 
cells and injury recruited cells. These cells release a variety of 
proinflammatory mediators including cytokines, chemokines, 
lipids and ROS that contribute to the demise of hepatocytes. 
Illustrating the importance of innate immunity, mice deficient 
in key mediators of LPS signalling such as TLR4, CD14 and 
MyD88 display better outcomes during liver disease.4 31 32 Here, 
we tested a hypothesised anti-inflammatory role for TREM-2 in 
liver disease.
We show that TREM-2 expression dramatically rises during 
various forms of liver injury in both mice and humans and that 
hepatic mouse TREM-2 is expressed on non-parenchymal KCs 
and HSCs. Nonetheless, we cannot be certain that in other 
species, including humans, TREM-2 is not expressed in hepato-
cytes during liver injury. Notably, although TREM-2 receptor 
expression has previously been detected on a variety of resident 
macrophages, including KCs,8 10 13 27 to our knowledge, this is 
the first study demonstrating TREM-2 expression on quiescent 
and activated HSCs, expanding on studies showing TREM-1 
expression on this important immune and fibrogenic cell type.12 
Further, we disclose that during HSC activation, TREM-2 is 
dramatically increased in a conserved manner and is upregulated 
within HSCs during chronic liver injury. However, TREM-2 
exerted unremarkable effects on HSC activation in vitro and in 
the context of chronic liver injury, effects consistent with minor 
effects of TREM-2 on fibrosis and the critical fibrogenic medi-
ator, TGFβ−1 during chronic injury.20 21 Further, as the net 
amount of collagen deposition is controlled by matrix metal-
loproteinases and their inhibitors, augmented Mmp13 levels 
observed in Trem-2-/- mice during repetitive injury could play 
a role in fibrosis resolution.33 Interestingly, although HSCs are 
not professional phagocytes, phagocytosis of apoptotic bodies 
by HSCs has been documented and postulated to promote HSC 
activation, survival, TGFβ−1 and collagen production.34–36 In 
some cell types, TREM-2 has been described to be important 
for the clearance of bacteria and apoptotic cells.11 16 27 37 Thus, 
defects in the uptake of apoptotic bodies by Trem-2-/- HSCs 
could additionally contribute to the minor effects of TREM-2 on 
fibrosis observed during chronic CCl4 injury. To summarise, our 
data indicate that TREM-2 primarily limits hepatocellular injury, 
a process that appears to be linked to its negative regulatory role 
during inflammation.
Similar to BM macrophages,8 TREM-2 dampened TLR4-
driven inflammation in KCs and HSCs. Higher inflamma-
tion in Trem-2-/- KCs correlated with effects of TREM-2 on 
TLR4-induced ERK activation, consistent with studies demon-
strating effects of TREM-2 on the ERK but not the NF-κB 
pathway.11 24 During acute CCl4-mediated injury, Trem-2
-/- mice 
exhibited enhanced numbers of liver neutrophils compared with 
WT, which correlated with elevated hepatic levels of the neutro-
phil chemoattractant CXCL1 and liver damage.38 The ability 
of TREM-2 to dampen CXCL1 and neutrophil recruitment 
following acute liver injury is consistent with how pulmonary 
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expressed TREM-2 reacts during early pneumococcal infec-
tion.27 Similarly, following acute APAP intoxication, augmented 
neutrophil influx was observed in Trem-2-/- livers. However, 
unlike acute CCl4 treatment hepatic macrophage content was also 
elevated in Trem-2-/- livers. Although the relative contribution of 
macrophages versus neutrophils to the enhanced liver injury of 
Trem-2-/- mice in the various models of liver injury remains to 
be determined, we importantly show that (1) TREM-2 dampens 
liver damage in all models tested; (2) lack of TREM-2 is asso-
ciated with worsened survival outcome following APAP chal-
lenge; (3) gut-derived PAMPs are a driver for acute liver injury 
of TREM-2 deficient mice.
In terms of mechanistic parallels between APAP intoxication 
and chronic CCl4 injury, we observed significantly enhanced 
Mcp1 levels in Trem-2-/- versus WT livers in both models, which 
was associated with more damage, macrophage levels and lipid 
peroxidation. Although resident KCs have a prenatal origin 
and are generated from the yolk sac and/or fetal liver, during 
liver injury, circulating Ly6C+ monocytes are recruited to the 
injured liver in a MCP-1/CCR-2 dependent manner, where 
they can contribute to injury.39–41 Indeed, it has recently been 
shown that hepatic infiltrating monocyte derived macrophages 
exert proinflammatory functions early after APAP and thereby 
promote liver injury. Consequently, reducing monocyte infiltra-
tion via MCP-1/CCR2 inhibition attenuates APAP-induced liver 
injury.42 Together, these data indicate that during acute toxic 
hepatic injury, the recruitment of monocytes to the liver perpet-
uates parenchymal damage, a hypothesis that is supported by 
studies indicating that KCs play a protective role in APAP-in-
duced injury.43 We now add to this knowledge by highlighting 
the importance of TREM-2 signalling for suppressing recruit-
ment of extrahepatic macrophages in toxic liver injury.
Our data suggest that TREM-2 dampens TLR4-dependent 
MCP-1 production within HSCs, impacting hepatic macro-
phage recruitment. Furthermore, TREM-2 expressed on these 
infiltrating macrophages blunts ROS production, thus limiting 
ROS-mediated hepatocellular lipid peroxidation and cell 
death. Effects of TREM-2 on ROS within infiltrating macro-
phages alone appears insufficient to dampen liver damage, as 
WT mice reconstituted with Trem-2-/- BM do not display more 
liver damage than WT mice with WT BM. Rather, our data 
suggest that TREM-2 effects on TLR4-dependent inflamma-
tory events in HSCs is critical for setting the stage for hepatic 
macrophage recruitment, a process influenced by HSC-derived 
MCP-1 and by ROS and cytokine production from infiltrating 
immune cells. These observations are concordant with data 
demonstrating that liver steatosis sensitises to CCl4 hepatotox-
icity, in part through oxidative stress.44 Supporting a cross-talk 
between infiltrating monocytes and HSCs in liver injury, puri-
fied Cd11b+F4/80+Ly6C+ cells derived from CCl4 treated mice 
can directly activate HSCs, promoting hepatocellular damage.45 
In this regard, it is interesting that infiltrating inflammatory 
Figure 9 PAMPs are upstream of TREM-2 during liver injury (A–C) WT and Trem-2-/- mice that either received antibiotics or not in their drinking 
water for 4 weeks were injured acutely with CCl4 and 8 hours postinjection were orally gavaged with 4KDa-fluorescein isothiocyanate (FITC) Dextran 
and sacrificed 4 hours later. Serum levels of FITC Dextran (A), AST/ALT (B) and qRT-PCR of liver Il6 and Il1b (C) were determined. Data represent 
mean±SEM and *, ** denote a P value of ˂0.05 and ˂0.01, respectively versus the indicated genotype and condition (Student’s t-test). n=8–9 mice 
per genotype and condition. Abx, antibiotics; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCl4, carbon tetrachloride; IL, interleukin; 
PAMPs, pathogen-associated molecular patterns; TREM, triggering receptor expressed on myeloid cells; WT, wild type. 
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Ly6C+ macrophages downregulate Ly6C on uptake of apoptotic 
hepatocytes and this is associated with a tissue protective pheno-
type following alcoholic-induced liver injury.46 Although the 
exact nature of infiltrating macrophages during injury in Trem-
2-/- mice in the models of liver injury requires further examina-
tion, our data, along with published observations, suggest they 
could be important for TREM-2 to limit hepatocellular damage 
following APAP intoxication and chronic CCl4 injury. Hepato-
cyte death would presumably release a variety of danger-associ-
ated molecular patterns, including heat-shock proteins, purine 
metabolites and mitochondrial DNA that can further provoke a 
vicious cycle of inflammation, macrophage recruitment and cell 
death.28 Such a hepatotoxic feed forward loop could be present 
and elevated in Trem-2-/- livers during chronic injury and APAP 
intoxication. Further, effects on TREM-2 on liver lipid metabo-
lism are reminiscent with very recent studies indicating TREM-2 
alters brain lipid metabolism and purogenic signalling in the 
context of cuprizone-induced oligodendrocyte injury and that 
TREM-2 can sense lipids.17 47 Highlighting the importance of 
TREM-2 in lipid metabolism, recent data indicate that TREM-2 
promotes adipogenesis and in vivo high fat diet fed mice over-
expressing TREM-2 were more obese and developed elevated 
hepatic steatosis versus controls.48 Although the authors of the 
aforementioned study did not perform an extensive analysis of 
TREM-2’s function in hepatic injury in this context, these data 
suggest TREM-2’s role in hepatocellular injury during non-alco-
holic fatty liver disease may be distinct and complex, involving 
not just its immune but also adipogenic and lipid regulatory 
functions.47 48
This is the first study demonstrating a role for TREM-2 in 
toxic liver injury and is reminiscent of published effects of 
TREM-2 in injury responses in other organ and tissue systems. 
For example, in the colon, TREM-2 has been reported to be 
important in wound-healing.15 In the brain, TREM-2 functions 
to clear apoptotic neurons and limit microglial proinflammatory 
responses.11 16 Our work suggests that TREM-2 could be an 
attractive target for promoting the resolution of inflammation 
during liver injury and for the prevention of parenchymal cell 
death, this akin to events described for TREM-2 in neuroinflam-
matory diseases and sepsis.16 49
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